+1 (202) 780-3397
Early identification of cognitive decline in metabolic syndrome
Joint Event on 10th WORLD HEART CONGRESS & 6th International Congress on CARDIOLOGY AND CARDIAC SURGERY
December 02-03, Dubai, UAE
Galya Naydenova Atanasova
Country Medical University of Pleven, Bulgaria
Posters & Accepted Abstracts : Curr Trend Cardiol
Abstract:
Background: Metabolic syndrome (MetS) may be a
prodromal manifestation of vascular cognitive impairment.
Diagnosing early stages of cerebrovascular pathology can lead
to prevention and delay of the progression of pathological
conditions such as vascular cognitive impairment.
Objective: The objective of the study was to investigate
new biomarkers for early diagnosis of MetS and cognitive
decline as a follow-up. A cardiological, neuropsychological
and neurological study was conducted among 75 Bulgarian
participants. Beta amyloid in the blood, procalcitonin
(PCT), NT-proBNP as predictors of cognitive impairment in
patients with metabolic syndrome were identified.
Methods: Clinical, anthropometric, biochemical,
neuropsychological, cognitive and statistical data
processing. Plasma amyloid beta (Aβ) levels, procalcitonin,
NT-proBNP in MetS were investigated in participants with
MetS and in group of healthy people.
Results: In the present study, plasma levels of Aβ42 and
Aβ40 were found to be reduced in MetS participants.
Procalcitonin concentration was significantly higher
in males than in females. NT-proBNP was significantly
higher in females than in males (p <0.001). Regression
analysis showed a positive relationship between NTproBNP
and systolic blood pressure (p <0.001) and fasting
blood glucose (p <0.05). An inverse relation between NTproBNP
and diastolic blood pressure, waist circumference,
triglycerides, HDL- and LDL cholesterol was found.
Conclusions: There was a positive association between
PCT levels, decreased levels of Aβ42 and Aβ40, as well as
elevated NT-proBNP and cognitive impairment in people
with MetC. A concentration of NT-proBNP of 60 pg / ml or
greater could be an indicator of metabolic abnormalities
and early cognitive decline.
Biography:
E-mail:
gal_na69@abv.bgPDF HTML